NCT06153095View on ClinicalTrials.gov

A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 15, 2024

Primary Completion Date

January 9, 2025

Study Completion Date

January 9, 2025

Conditions
Systemic Lupus ErythematosusLupus Nephritis
Interventions
BIOLOGICAL

IMPT-514

CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide

BIOLOGICAL

IMPT-514

CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide

BIOLOGICAL

IMPT-514

CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide

Trial Locations (4)

52242

University of Iowa, Iowa City

90095

University of California, Los Angeles (UCLA) Medical Center, Los Angeles

94143

University of California San Francisco, San Francisco

NSW 2145

Westmead Hospital, Westmead

Sponsors
All Listed Sponsors
lead

Lyell Immunopharma, Inc.

INDUSTRY